Don't invest unless you're prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.

Don't invest unless you're prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. .

Menu

Articles

Read articles and interviews on investing in startups, venture capital funds, tax saving and retirement planning strategies and the latest industry trends, from diversity to cleantech and sustainability. You''ll also find interviews and podcasts with our founders and angel investors.

An angel’s prescription: Pam Garside’s guide to spotting winning health tech founders

15 September 2025

An angel’s prescription: Pam Garside’s guide to spotting winning health tech founders

Pam Garside has a unique perspective on the world of angel investing. With a long and distinguished career in healthcare, she has become a prominent angel investor, particularly in the health tech sector. She's also the first female chair of Cambridge Angels, a well-known group of angel investors in the UK. In a recent conversation, Pam shared her journey, insights on due diligence, and her passion for helping founders succeed.

The data behind the Access EIS Fund

11 September 2025

The data behind the Access EIS Fund

Based on a comprehensive analysis of the UK venture capital market, the Access EIS Fund offers a strategy grounded in quantitative data rather than traditional intuition. It employs a unique model which harnesses this data analysis through co-investment with leading UK angel investors and builds investors large portfolios of high-potential startups.

Béa Fertility: revolutionising fertility care for modern families

Béa Fertility: revolutionising fertility care for modern families

When Tess Cosad founded Béa Fertility, she set out to solve a problem that affects millions of people worldwide: making fertility treatment more accessible, affordable, and effective. What began as an idea to reimagine the fertility care journey has evolved into a groundbreaking company that's changing how modern families approach conception, with clinical results that speak for themselves.

Century Tech: personalising education through artificial intelligence

Century Tech: personalising education through artificial intelligence

In the rapidly evolving landscape of educational technology, Priya Lakhani OBE recognised that traditional one-size-fits-all teaching methods were failing to unlock the potential of individual learners. Her vision for Century Tech emerged from a deep understanding that artificial intelligence could revolutionise education by providing personalised learning experiences at scale. What began as an ambitious concept has evolved into an award-winning platform that's transforming how students learn and teachers teach across the UK and beyond.

Presenting Access EIS 2.0: a smarter approach to startup investing

Presenting Access EIS 2.0: a smarter approach to startup investing

We are thrilled to announce the relaunch of our flagship fund, Access EIS. This updated version, which we're fondly calling Access 2.0, is the culmination of extensive research and analysis of the startup market, designed to provide our investors with an even more robust and data-driven investment strategy.

SEIS Fund VIII: Carbon13 targets top-quartile returns

SEIS Fund VIII: Carbon13 targets top-quartile returns

SEIS Fund VIII by Carbon13 targets top-quartile returns through climate tech startups. Invest in purpose-driven companies addressing climate change with significant tax benefits.

SEIS investment surges as government reforms unlock early-stage funding

SEIS investment surges as government reforms unlock early-stage funding

The Seed Enterprise Investment Scheme has experienced remarkable growth, with investment levels reaching £242 million in 2023-24 (HMRC), representing a substantial 51% increase from the previous year's £160 million. This dramatic surge demonstrates the scheme's growing importance in the UK's early-stage investment ecosystem and reflects both policy reforms and increased investor appetite for tax-efficient startup funding.

Re-Vana Therapeutics secures landmark $1 billion partnership with Boehringer Ingelheim

Re-Vana Therapeutics secures landmark $1 billion partnership with Boehringer Ingelheim

Re-Vana Therapeutics, a SyndicateRoom portfolio company, has announced a transformational strategic collaboration with global pharmaceutical leader Boehringer Ingelheim, marking a landmark moment for both the Northern Ireland biotech company and the UK's life sciences sector.

How Angela Cretu transformed Avon and now backs female founders

How Angela Cretu transformed Avon and now backs female founders

How Angela Cretu transformed Avon and now backs female founders through Angel Academe. Read her insights on women's empowerment in business and startup investment.

Load more articles

Showing 9 of 118 articles

Risk warning: Please click here to read the full risk warning.

Investing in early-stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance.

This page has been approved as a financial promotion by Syndicate Room Ltd, which is authorised and regulated by the Financial Conduct Authority (No. 613021).

We use cookies to improve our service. By continuing to use this site you are agreeing to their use. Find out more. .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Syndicate Room Ltd is registered in England and Wales. Number 07697935. Registered office: Wellington House, East Road, Cambridge, Cambridgeshire, CB1 1BH, United Kingdom

General enquiries

Please note: our office hours are weekdays, 9.30am - 5.30pm.

Email:

contactus@syndicateroom.com

Phone:

Existing investors

Email:

investor.relations@syndicateroom.com

Phone:

Articles (page 6)